You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMemantine
Accession NumberDB01043  (APRD00221)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionMemantine is an amantadine derivative with low to moderate-affinity for NMDA receptors. It is a noncompetitive NMDA receptor antagonist that binds preferentially to NMDA receptor-operated cation channels. It blocks the effects of excessive levels of glutamate that may lead to neuronal dysfunction. It is under investigation for the treatment of Alzheimer's disease, but there has been no clinical support for the prevention or slowing of disease progression.
Structure
Thumb
Synonyms
1-Amino-3,5-dimethyladamantane
1,3-Dimethyl-5-adamantanamine
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
Memantina
Memantine
Memantinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act MemantineTablet10 mgOralActavis Pharma Company2010-02-18Not applicableCanada
Act MemantineTablet5 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
AxuraTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
AxuraTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2002-05-17Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaSolution5 mg/Pump actuationOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaSolution5 mg/Pump actuationOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet10 mgOralLundbeck Canada Inc2004-12-16Not applicableCanada
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaSolution5 mg/Pump actuationOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated20 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
EbixaTablet, film coated10 mgOralH. Lundbeck A/S2002-05-15Not applicableEu
Med-memantineTablet5 mgOralGeneric Medical Partners IncNot applicableNot applicableCanada
Med-memantineTablet10 mgOralGeneric Medical Partners Inc2015-02-03Not applicableCanada
MemantineTablet10 mgOralMeliapharm Inc2011-07-272014-06-25Canada
MemantineTablet10 mgOralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
MemantineTablet10 mgOralSanis Health Inc2015-07-22Not applicableCanada
Memantine HydrochlorideKitOralActavis Pharma, Inc2015-04-01Not applicableUs
Memantine HydrochlorideSolution2 mg/mLOralActavis Pharma, Inc2015-04-01Not applicableUs
Memantine HydrochlorideTablet5 mg/1OralActavis Pharma, Inc2015-04-01Not applicableUs
Memantine HydrochlorideTablet10 mg/1OralActavis Pharma, Inc2015-04-01Not applicableUs
Memantine Hydrochloride TabletsTablet10 mgOralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
Memantine MerzTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzSolution5 mg / pump actuationOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzSolution5 mg / pump actuationOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated20 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzTablet, film coated10 mgOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Memantine MerzSolution5 mg / pump actuationOralMerz Pharmaceuticals Gmb H  2012-11-22Not applicableEu
Mylan-memantineTablet10 mgOralMylan Pharmaceuticals Ulc2015-04-07Not applicableCanada
NamendaKitOralForest Laboratories, Inc.2003-10-16Not applicableUs
NamendaTablet5 mg/1Oralbryant ranch prepack2003-10-16Not applicableUs
NamendaTablet10 mg/1OralCardinal Health2003-10-16Not applicableUs
NamendaTablet10 mg/1OralRebel Distributors Corp2004-11-17Not applicableUs
NamendaTablet10 mg/1Oralbryant ranch prepack2003-10-16Not applicableUs
NamendaSolution2 mg/mLOralForest Laboratories, Inc.2005-04-18Not applicableUs
NamendaTablet5 mg/1OralCardinal Health2003-10-16Not applicableUs
NamendaTablet5 mg/1OralRebel Distributors Corp2006-08-09Not applicableUs
NamendaTablet5 mg/1OralForest Laboratories, Inc.2003-10-16Not applicableUs
NamendaTablet10 mg/1OralContract Pharmacy Services Pa2010-03-19Not applicableUs
NamendaTablet10 mg/1OralCardinal Health2003-10-16Not applicableUs
NamendaTablet10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-03Not applicableUs
NamendaTablet10 mg/1OralForest Laboratories, Inc.2003-10-16Not applicableUs
NamendaTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2003-10-16Not applicableUs
Namenda XRCapsule, extended release21 mg/1OralAllergan, Inc.2011-10-31Not applicableUs
Namenda XRKitOralAllergan, Inc.2011-09-15Not applicableUs
Namenda XRCapsule, extended release14 mg/1OralCarilion Materials Management2011-10-31Not applicableUs
Namenda XRCapsule, extended release28 mg/1OralAllergan, Inc.2011-10-31Not applicableUs
Namenda XRCapsule, extended release7 mg/1OralAllergan, Inc.2011-10-31Not applicableUs
Namenda XRCapsule, extended release28 mg/1OralCarilion Materials Management2011-10-31Not applicableUs
Namenda XRCapsule, extended release28 mg/1OralAvera Mc Kennan Hospital2015-03-02Not applicableUs
Namenda XRCapsule, extended release14 mg/1OralAllergan, Inc.2011-10-31Not applicableUs
Namenda XRCapsule, extended release28 mg/1OralCarilion Materials Management2011-10-31Not applicableUs
Namenda XRCapsule, extended release7 mg/1OralAvera Mc Kennan Hospital2015-03-16Not applicableUs
Novo-memantineTablet10 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Novo-memantineTablet5 mgOralTeva Canada LimitedNot applicableNot applicableCanada
PMS-memantineTablet10 mgOralPharmascience Inc2009-11-04Not applicableCanada
PMS-memantineTablet5.0 mgOralPharmascience Inc2015-03-02Not applicableCanada
Ran-memantineTablet10 mgOralRanbaxy Pharmaceuticals Canada Inc.2014-07-16Not applicableCanada
Ratio-memantineTablet10 mgOralTeva Canada Limited2009-10-30Not applicableCanada
Riva-memantineTablet10 mgOralLaboratoire Riva Inc2010-06-14Not applicableCanada
Sandoz MemantineTablet10 mgOralSandoz Canada Incorporated2010-04-16Not applicableCanada
Sandoz Memantine FctTablet10 mgOralSandoz Canada Incorporated2014-07-17Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-memantineTablet10 mgOralApotex Inc2011-06-17Not applicableCanada
MarixinoTablet, film coated10 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated20 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated20 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated10 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated20 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated10 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated20 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated10 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated20 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated10 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated20 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated20 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated10 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated20 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated10 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated10 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated20 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated10 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated20 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated10 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated20 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated10 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated10 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated20 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated10 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MarixinoTablet, film coated20 mgOralConsilient Health Ltd2013-04-29Not applicableEu
MemantineTablet5 mg/1OralAmerican Health Packaging2015-08-15Not applicableUs
MemantineTablet10 mg/1OralCardinal Health2015-07-20Not applicableUs
MemantineTablet10 mg/1OralMajor Pharmaceuticals2015-07-20Not applicableUs
MemantineTablet10 mg/1OralAmerican Health Packaging2015-08-15Not applicableUs
MemantineTablet5 mg/1OralDr. Reddys Laboratories Limited2015-07-11Not applicableUs
MemantineTablet10 mg/1OralDr. Reddys Laboratories Limited2015-07-11Not applicableUs
MemantineTablet5 mg/1OralMajor Pharmaceuticals2015-07-20Not applicableUs
Memantine AccordTablet, film coated20 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine AccordTablet, film coated10 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine AccordTablet, film coated10 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine AccordTablet, film coated20 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine AccordTablet, film coated10 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine AccordTablet, film coated10 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine AccordTablet, film coated20 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine AccordTablet, film coated10 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine AccordTablet, film coated20 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine AccordTablet, film coated10 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine AccordTablet, film coated10 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine AccordTablet, film coated10 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine AccordTablet, film coated20 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine AccordTablet, film coated10 mgOralAccord Healthcare Limited2013-12-04Not applicableEu
Memantine HydrochlorideTablet5 mg/1OralAjanta Pharma Limited2015-08-27Not applicableUs
Memantine HydrochlorideTablet, film coated10 mg/1OralUpsher Smith Laboratories, Inc2015-07-31Not applicableUs
Memantine HydrochlorideTablet10 mg/1OralWockhardt USA LLC.2015-09-04Not applicableUs
Memantine HydrochlorideTablet5 mg/1OralMylan Pharmaceuticals Inc.2015-07-11Not applicableUs
Memantine HydrochlorideTablet10 mg/1OralMylan Institutional Inc.2015-07-31Not applicableUs
Memantine HydrochlorideSolution2 mg/mLOralMacleods Pharmaceuticals Limited2015-10-13Not applicableUs
Memantine HydrochlorideTablet5 mg/1OralVivimed Labs Limited2015-09-04Not applicableUs
Memantine HydrochlorideTablet5 mg/1OralPura Cap Pharmaceutical Llc2016-02-22Not applicableUs
Memantine HydrochlorideTablet, film coated5 mg/1OralAmneal Pharmaceuticals of New York, LLC2015-04-30Not applicableUs
Memantine HydrochlorideTablet, film coated5 mg/1OralLupin Pharmaceuticals, Inc.2015-07-13Not applicableUs
Memantine HydrochlorideTablet, film coated5 mg/1OralAv Kare, Inc.2016-01-11Not applicableUs
Memantine HydrochlorideTablet10 mg/1OralAjanta Pharma Limited2015-08-27Not applicableUs
Memantine HydrochlorideLiquid2 mg/mLOralPatrin Pharma2016-06-01Not applicableUs
Memantine HydrochlorideTablet, film coated5 mg/1OralSun Pharma Global FZE2015-07-11Not applicableUs
Memantine HydrochlorideKitWockhardt USA LLC.2015-09-04Not applicableUs
Memantine HydrochlorideTablet10 mg/1OralMylan Pharmaceuticals Inc.2015-07-11Not applicableUs
Memantine HydrochlorideTablet10 mg/1OralPura Cap Pharmaceutical Llc2016-02-22Not applicableUs
Memantine HydrochlorideTablet5 mg/1OralMacleods Pharmaceuticals Limited2015-10-12Not applicableUs
Memantine HydrochlorideTablet, film coated5 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-10-14Not applicableUs
Memantine HydrochlorideTablet10 mg/1OralVivimed Labs Limited2015-09-04Not applicableUs
Memantine HydrochlorideTablet, film coated10 mg/1OralLupin Pharmaceuticals, Inc.2015-07-13Not applicableUs
Memantine HydrochlorideTablet5 mg/1OralTorrent Pharmaceuticals Limited2015-10-13Not applicableUs
Memantine HydrochlorideTablet, film coated5 mg/1OralUnichem Pharmaceuticals (USA), Inc.2015-11-01Not applicableUs
Memantine HydrochlorideTablet, coated10 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-10-13Not applicableUs
Memantine HydrochlorideTablet, coated5 mg/1OralAlembic Pharmaceuticals Inc.2015-10-13Not applicableUs
Memantine HydrochlorideTablet, film coated10 mg/1OralAv Kare, Inc.2016-01-11Not applicableUs
Memantine HydrochlorideSolution2 mg/mLOralLannett Company, Inc.2015-10-13Not applicableUs
Memantine HydrochlorideTablet, film coated10 mg/1OralSun Pharma Global FZE2015-07-11Not applicableUs
Memantine HydrochlorideTablet, film coated5 mg/1OralAurobindo Pharma Limited2015-10-13Not applicableUs
Memantine HydrochlorideTablet10 mg/1OralMacleods Pharmaceuticals Limited2015-10-12Not applicableUs
Memantine HydrochlorideTablet, film coated10 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-10-14Not applicableUs
Memantine HydrochlorideKitVivimed Labs Limited2015-09-04Not applicableUs
Memantine HydrochlorideTablet10 mg/1OralTorrent Pharmaceuticals Limited2015-10-13Not applicableUs
Memantine HydrochlorideTablet, film coated5 mg/1OralUpsher Smith Laboratories, Inc2015-07-31Not applicableUs
Memantine HydrochlorideTablet, film coated10 mg/1OralUnichem Pharmaceuticals (USA), Inc.2015-11-01Not applicableUs
Memantine HydrochlorideTablet, film coated10 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-07-31Not applicableUs
Memantine HydrochlorideTablet, coated10 mg/1OralAlembic Pharmaceuticals Inc.2015-10-13Not applicableUs
Memantine HydrochlorideTablet, film coated10 mg/1OralAmneal Pharmaceuticals of New York, LLC2015-04-30Not applicableUs
Memantine HydrochlorideTablet, film coated10 mg/1OralAurobindo Pharma Limited2015-10-13Not applicableUs
Memantine HydrochlorideTablet5 mg/1OralMylan Institutional Inc.2015-08-24Not applicableUs
Memantine HydrochlorideTablet5 mg/1OralWockhardt USA LLC.2015-09-04Not applicableUs
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated10 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine MylanTablet, film coated20 mgOralGenerics [Uk] Limited2013-04-22Not applicableEu
Memantine RatiopharmTablet, film coated10 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated10 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated20 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated20 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated10 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated20 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated10 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated10 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated20 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated20 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated10 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated20 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated10 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated10 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated20 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated20 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated10 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated10 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated10 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated20 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated10 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Memantine RatiopharmTablet, film coated20 mgOralRatiopharm Gmb H2013-06-13Not applicableEu
Mematine HydrochlorideTablet, film coated10 mg/1OralOrchid Chemicals & Pharmaceuticals Limited2015-01-11Not applicableUs
Mematine HydrochlorideTablet, film coated5 mg/1OralOrchid Chemicals & Pharmaceuticals Limited2015-01-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbixaNot Available
AkatinolNot Available
AxuraNot Available
MemoxNot Available
Brand mixtures
NameLabellerIngredients
NamzaricAllergan, Inc.
Salts
Name/CASStructureProperties
Memantine Hydrochloride
41100-52-1
Thumb
  • InChI Key: LDDHMLJTFXJGPI-UHFFFAOYNA-N
  • Monoisotopic Mass: 215.144077416
  • Average Mass: 215.763
DBSALT000456
Categories
UNIIW8O17SJF3T
CAS number19982-08-2
WeightAverage: 179.3018
Monoisotopic: 179.167399677
Chemical FormulaC12H21N
InChI KeyBUGYDGFZZOZRHP-UHFFFAOYSA-N
InChI
InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3
IUPAC Name
3,5-dimethyladamantan-1-amine
SMILES
CC12CC3CC(C)(C1)CC(N)(C3)C2
Pharmacology
IndicationFor the treatment of moderate to severe dementia of the Alzheimer's type.
Structured Indications
PharmacodynamicsMemantine, an amantadine derivative, is an NMDA receptor antagonist used in the treatment of Alzheimer's disease. It differs from traditional agents used in Alzheimer's disease by acting on glutamatergic neurotransmission, rather than cholinergic. There is some evidence that dysfunction of glutamatergic neurotransmission, manifested as neuronal excitotoxicity, is involved in the aetiology of Alzheimer's disease (Cacabelos et al., 1999). As such, targeting the glutamatergic system, specifically NMDA receptors, was a novel approach to treatment in view of the limited efficacy of existing drugs targeting the cholinergic system. A systematic review of randomised controlled trials found that memantine has a positive effect on cognition, mood, behaviour, and the ability to perform daily activities. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer's disease.
Mechanism of actionMemantine exerts its action through uncompetitive NMDA receptor antagonism, binding preferentially to the NMDA receptor-operated cation channels. Prolonged increased levels of glutamate in the brain of demented patients are sufficient to counter the voltage-dependent block of NMDA receptors by Mg2+ ions and allow continuous influx of Ca2+ ions into cells, ultimately resulting in neuronal degeneration. Studies suggest that memantine binds more effectively than Mg2+ ions at the NMDA receptor, and thereby effectively blocks this prolonged influx of Ca2+ ions through the NMDA channel whilst preserving the transient physiological activation of the channels by higher concentrations of synaptically released glutamate. Thus memantine protects against chronically elevated concentrations of glutamate. Memantine also has antagonistic activity at the type 3 serotonergic (5-HT3) receptor with a potency that is similar to that at the NMDA receptor, and lower antagonistic activity at the nicotinic acetylcholine receptor. This drug has no affinity for γ-aminobutyric acid (GABA), benzodiazepine, dopamine, adrenergic, histamine, or glycine receptors or for voltage-dependent calcium, sodium, or potassium channels.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glutamate receptor ionotropic, NMDA 3AProteinyes
antagonist
HumanQ8TCU5 details
Glutamate receptor ionotropic, NMDA 2AProteinyes
antagonist
HumanQ12879 details
Glutamate receptor ionotropic, NMDA 2BProteinyes
antagonist
HumanQ13224 details
5-hydroxytryptamine receptor 3AProteinunknown
antagonist
HumanP46098 details
Alpha-7 nicotinic cholinergic receptor subunitProteinunknown
antagonist
HumanQ693P7 details
D(2) dopamine receptorProteinunknown
agonist
HumanP14416 details
Glutamate receptor ionotropic, NMDA 1Proteinunknown
binder
HumanQ05586 details
Related Articles
AbsorptionWell absorbed orally with a bioavailability of approximately 100%. Peak plasma concentrations are reached in 3-7 hours. Food has no effect on absorption.
Volume of distribution
  • 9 to 11 L/kg
Protein binding45%
Metabolism

Excreted largely unchanged. About 20% is metabolized to 1-amino-3-hydroxymethyl-5-methyl-adamantane and 3-amino-1-hydroxy-5,7-dimethyl-adamantane.

SubstrateEnzymesProduct
Memantine
Not Available
1-amino-3-hydroxymethyl-5-methyl-adamantaneDetails
Memantine
Not Available
3-amino-1-hydroxy-5,7-dimethyl-adamantaneDetails
Route of eliminationMemantine undergoes partial hepatic metabolism. About 48% of administered drug is excreted unchanged in urine; the remainder is converted primarily to three polar metabolites which possess minimal NMDA receptor antagonistic activity: the N-glucuronide conjugate, 6-hydroxy memantine, and 1-nitroso-deaminated memantine. It is excreted predominantly in the urine, unchanged.
Half life60-100 hours
ClearanceNot Available
ToxicitySide effects include pain, abnormal crying, leg pain, fever, increased apetite. Adverse drug reactions include: dizziness, confusion, headache, hallucinations, tiredness. Less common side effects include: vomiting, anxiety, hypertonia, cystitis, and increased libido. Doses of up to 400 mg have been tolerated.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Memantine.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Memantine.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Memantine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Memantine.Experimental, Illicit
AcebutololMemantine may increase the bradycardic activities of Acebutolol.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Memantine which could result in a higher serum level.Approved, Vet Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Memantine is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Memantine.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Memantine.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Memantine.Experimental
AlprenololMemantine may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
Aluminum hydroxideThe serum concentration of Memantine can be increased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Memantine can be increased when it is combined with Aluminum phosphate.Approved
AmantadineThe risk or severity of adverse effects can be increased when Amantadine is combined with Memantine.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Memantine.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Memantine.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Memantine.Approved
Aop200704Memantine may increase the bradycardic activities of Aop200704.Investigational
ArecolineThe risk or severity of adverse effects can be increased when Memantine is combined with Arecoline.Experimental
ArotinololMemantine may increase the bradycardic activities of Arotinolol.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Memantine resulting in a loss in efficacy.Approved
AtenololMemantine may increase the bradycardic activities of Atenolol.Approved
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Memantine.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Memantine.Approved, Vet Approved
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Memantine.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Memantine.Approved, Investigational
BefunololMemantine may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Memantine.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Memantine.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Memantine.Approved, Vet Approved
BetaxololMemantine may increase the bradycardic activities of Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Memantine is combined with Bethanechol.Approved
BevantololMemantine may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Memantine.Approved
Bismuth SubcitrateThe serum concentration of Memantine can be increased when it is combined with Bismuth Subcitrate.Approved
BisoprololMemantine may increase the bradycardic activities of Bisoprolol.Approved
BopindololMemantine may increase the bradycardic activities of Bopindolol.Approved
BrinzolamideBrinzolamide may decrease the excretion rate of Memantine which could result in a higher serum level.Approved
BucindololMemantine may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Memantine.Approved
BufuralolMemantine may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololMemantine may increase the bradycardic activities of Bupranolol.Approved
BupropionThe serum concentration of Memantine can be increased when it is combined with Bupropion.Approved
Calcium carbonateThe serum concentration of Memantine can be increased when it is combined with Calcium carbonate.Approved
CarbacholThe risk or severity of adverse effects can be increased when Memantine is combined with Carbachol.Approved
CarteololMemantine may increase the bradycardic activities of Carteolol.Approved
CarvedilolMemantine may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololMemantine may increase the bradycardic activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Memantine is combined with Cevimeline.Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Memantine.Withdrawn
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Memantine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Memantine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Memantine.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Memantine.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Memantine.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Memantine.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Memantine.Approved
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Memantine.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Memantine.Investigational
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Memantine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Memantine.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Memantine.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Memantine.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Memantine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Memantine.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Memantine.Withdrawn
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Memantine.Approved
DiclofenamideDiclofenamide may decrease the excretion rate of Memantine which could result in a higher serum level.Approved
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Memantine.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Memantine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Memantine.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Memantine.Approved
DipyridamoleThe therapeutic efficacy of Memantine can be decreased when used in combination with Dipyridamole.Approved
DorzolamideDorzolamide may decrease the excretion rate of Memantine which could result in a higher serum level.Approved
EPIBATIDINEThe risk or severity of adverse effects can be increased when Memantine is combined with EPIBATIDINE.Experimental
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Memantine.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Memantine.Approved
EsmololMemantine may increase the bradycardic activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Memantine.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Memantine.Approved
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Memantine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Memantine which could result in a higher serum level.Withdrawn
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Memantine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Memantine.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Memantine.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Memantine.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Memantine.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Memantine.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Memantine.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Memantine.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Memantine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Memantine.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Memantine.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Memantine.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Memantine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Memantine.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Memantine.Approved, Investigational, Withdrawn
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Memantine.Approved
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Memantine.Approved, Investigational, Vet Approved
GTS-21The risk or severity of adverse effects can be increased when Memantine is combined with GTS-21.Investigational
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Memantine.Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Memantine.Experimental
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Memantine.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Memantine.Approved, Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Memantine.Approved
IndenololMemantine may increase the bradycardic activities of Indenolol.Withdrawn
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Memantine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Memantine.Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Memantine.Approved, Vet Approved
LabetalolMemantine may increase the bradycardic activities of Labetalol.Approved
LevobunololMemantine may increase the bradycardic activities of Levobunolol.Approved
LobelineThe risk or severity of adverse effects can be increased when Memantine is combined with Lobeline.Investigational
MagaldrateThe serum concentration of Memantine can be increased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Memantine can be increased when it is combined with Magnesium carbonate.Approved
Magnesium hydroxideThe serum concentration of Memantine can be increased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Memantine can be increased when it is combined with Magnesium oxide.Approved
Magnesium TrisilicateThe serum concentration of Memantine can be increased when it is combined with Magnesium Trisilicate.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Memantine.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Memantine.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Memantine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Memantine.Vet Approved
MethacholineThe risk or severity of adverse effects can be increased when Memantine is combined with Methacholine.Approved
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Memantine.Approved
MethazolamideMethazolamide may decrease the excretion rate of Memantine which could result in a higher serum level.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Memantine.Approved, Vet Approved
MetipranololMemantine may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Memantine.Approved
MetoprololMemantine may increase the bradycardic activities of Metoprolol.Approved, Investigational
MivacuriumMemantine may decrease the neuromuscular blocking activities of Mivacurium.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Memantine.Approved, Vet Approved
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with Memantine.Vet Approved
NadololMemantine may increase the bradycardic activities of Nadolol.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Memantine.Investigational
NicotineThe risk or severity of adverse effects can be increased when Memantine is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Memantine is combined with Nicotine bitartrate.Approved
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with Memantine.Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Memantine.Investigational
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Memantine.Approved
OxprenololMemantine may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Memantine.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Memantine.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Memantine.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Memantine.Approved
PenbutololMemantine may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Memantine.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Memantine is combined with Pilocarpine.Approved
PindololMemantine may increase the bradycardic activities of Pindolol.Approved
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Memantine.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Memantine.Approved
PractololMemantine may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Memantine.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Memantine.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Memantine.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Memantine.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Memantine.Experimental
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Memantine.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Memantine.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Memantine.Investigational
PropranololMemantine may increase the bradycardic activities of Propranolol.Approved, Investigational
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Memantine.Approved
RapacuroniumMemantine may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Memantine.Approved
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Memantine.Approved
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Memantine.Approved
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Memantine.Approved
SotalolMemantine may increase the bradycardic activities of Sotalol.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Memantine.Approved
TimololMemantine may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Memantine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Memantine.Approved
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Memantine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Memantine.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Memantine.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Memantine.Approved
TrimethoprimThe risk or severity of adverse effects can be increased when Trimethoprim is combined with Memantine.Approved, Vet Approved
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Memantine.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Memantine.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Memantine.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Memantine.Approved
VareniclineThe risk or severity of adverse effects can be increased when Memantine is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Memantine.Approved
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

DrugSyn.org

US3391142
General References
  1. Cacabelos R, Takeda M, Winblad B: The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int J Geriatr Psychiatry. 1999 Jan;14(1):3-47. [PubMed:10029935 ]
  2. Rogawski MA, Wenk GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003 Fall;9(3):275-308. [PubMed:14530799 ]
  3. Robinson DM, Keating GM: Memantine: a review of its use in Alzheimer's disease. Drugs. 2006;66(11):1515-34. [PubMed:16906789 ]
  4. Rogawski MA: Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents--toward an understanding of their favorable tolerability. Amino Acids. 2000;19(1):133-49. [PubMed:11026482 ]
  5. Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG: The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett. 2001 Jun 22;306(1-2):81-4. [PubMed:11403963 ]
External Links
ATC CodesN06DX01N06DA53N06DA52
AHFS Codes
  • 28:92.00
PDB EntriesNot Available
FDA labelDownload (102 KB)
MSDSDownload (65.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9939
Blood Brain Barrier+0.9823
Caco-2 permeable+0.6082
P-glycoprotein substrateNon-substrate0.6403
P-glycoprotein inhibitor INon-inhibitor0.82
P-glycoprotein inhibitor IINon-inhibitor0.7555
Renal organic cation transporterNon-inhibitor0.7774
CYP450 2C9 substrateNon-substrate0.8213
CYP450 2D6 substrateNon-substrate0.6153
CYP450 3A4 substrateNon-substrate0.5319
CYP450 1A2 substrateNon-inhibitor0.9327
CYP450 2C9 inhibitorNon-inhibitor0.9281
CYP450 2D6 inhibitorNon-inhibitor0.872
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6795
Ames testNon AMES toxic0.6945
CarcinogenicityNon-carcinogens0.7426
BiodegradationNot ready biodegradable0.9633
Rat acute toxicity2.3455 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9839
hERG inhibition (predictor II)Non-inhibitor0.6818
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral5 mg
Tablet, film coatedOral10 mg
Tablet, film coatedOral20 mg
SolutionOral5 mg/Pump actuation
TabletOral10 mg
Kit
LiquidOral2 mg/mL
TabletOral10 mg/1
TabletOral5 mg/1
Tablet, coatedOral10 mg/1
Tablet, coatedOral5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
SolutionOral5 mg / pump actuation
KitOral
SolutionOral2 mg/mL
Capsule, extended releaseOral14 mg/1
Capsule, extended releaseOral21 mg/1
Capsule, extended releaseOral28 mg/1
Capsule, extended releaseOral7 mg/1
CapsuleOral
TabletOral5.0 mg
Prices
Unit descriptionCostUnit
Namenda 10 mg tablet3.38USD tablet
Namenda 5 mg tablet3.32USD tablet
Namenda 5-10 mg titration pk3.32USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2426492 No2006-10-032023-05-08Canada
US5061703 Yes1995-10-112015-10-11Us
US8039009 Yes2009-09-242029-09-24Us
US8058291 No2009-12-052029-12-05Us
US8168209 Yes2006-05-222026-05-22Us
US8173708 Yes2006-05-222026-05-22Us
US8283379 Yes2006-05-222026-05-22Us
US8293794 No2005-11-222025-11-22Us
US8329752 Yes2006-05-222026-05-22Us
US8338485 No2005-11-222025-11-22Us
US8338486 No2005-11-222025-11-22Us
US8362085 Yes2006-05-222026-05-22Us
US8580858 No2005-11-222025-11-22Us
US8598233 Yes2006-05-222026-05-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point258 °CPhysProp
water solubility35 mg/mL (HCl salt), 0.9 mg/mL for free baseNot Available
logP3.28HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0455 mg/mLALOGPS
logP3.31ALOGPS
logP2.07ChemAxon
logS-3.6ALOGPS
pKa (Strongest Basic)10.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity54.49 m3·mol-1ChemAxon
Polarizability21.82 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cyclohexylamines. These are organic compounds containing a cyclohexylamine moiety, which consist of a cyclohexane ring attached to an amine group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassCyclohexylamines
Sub ClassNot Available
Direct ParentCyclohexylamines
Alternative Parents
Substituents
  • Cyclohexylamine
  • Hydrocarbon derivative
  • Primary amine
  • Primary aliphatic amine
  • Amine
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein phosphatase 2a binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
Gene Name:
GRIN3A
Uniprot ID:
Q8TCU5
Molecular Weight:
125464.07 Da
References
  1. Smothers CT, Woodward JJ: Pharmacological characterization of glycine-activated currents in HEK 293 cells expressing N-methyl-D-aspartate NR1 and NR3 subunits. J Pharmacol Exp Ther. 2007 Aug;322(2):739-48. Epub 2007 May 14. [PubMed:17502428 ]
  2. Chatterton JE, Awobuluyi M, Premkumar LS, Takahashi H, Talantova M, Shin Y, Cui J, Tu S, Sevarino KA, Nakanishi N, Tong G, Lipton SA, Zhang D: Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature. 2002 Feb 14;415(6873):793-8. Epub 2002 Jan 30. [PubMed:11823786 ]
  3. Schrattenholz A, Soskic V: NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling. Curr Top Med Chem. 2006;6(7):663-86. [PubMed:16719808 ]
  4. Foster AC, Kemp JA: Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. Epub 2005 Dec 22. [PubMed:16377242 ]
  5. Rogawski MA, Wenk GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003 Fall;9(3):275-308. [PubMed:14530799 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of subunits.
Gene Name:
GRIN2A
Uniprot ID:
Q12879
Molecular Weight:
165281.215 Da
References
  1. Chen HS, Lipton SA: Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels. J Pharmacol Exp Ther. 2005 Sep;314(3):961-71. Epub 2005 May 18. [PubMed:15901795 ]
  2. Maler JM, Esselmann H, Wiltfang J, Kunz N, Lewczuk P, Reulbach U, Bleich S, Ruther E, Kornhuber J: Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. Brain Res. 2005 Aug 9;1052(2):156-62. [PubMed:16009352 ]
  3. Bresink I, Benke TA, Collett VJ, Seal AJ, Parsons CG, Henley JM, Collingridge GL: Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br J Pharmacol. 1996 Sep;119(2):195-204. [PubMed:8886398 ]
  4. Blanpied TA, Boeckman FA, Aizenman E, Johnson JW: Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol. 1997 Jan;77(1):309-23. [PubMed:9120573 ]
  5. Rogawski MA, Wenk GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003 Fall;9(3):275-308. [PubMed:14530799 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an ...
Gene Name:
GRIN2B
Uniprot ID:
Q13224
Molecular Weight:
166365.885 Da
References
  1. Kashiwagi K, Masuko T, Nguyen CD, Kuno T, Tanaka I, Igarashi K, Williams K: Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore. Mol Pharmacol. 2002 Mar;61(3):533-45. [PubMed:11854433 ]
  2. Nakazato E, Kato A, Watanabe S: Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model. Pharmacology. 2005 Jan;73(1):8-14. Epub 2004 Sep 27. [PubMed:15452358 ]
  3. Maler JM, Esselmann H, Wiltfang J, Kunz N, Lewczuk P, Reulbach U, Bleich S, Ruther E, Kornhuber J: Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. Brain Res. 2005 Aug 9;1052(2):156-62. [PubMed:16009352 ]
  4. Blanpied TA, Boeckman FA, Aizenman E, Johnson JW: Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol. 1997 Jan;77(1):309-23. [PubMed:9120573 ]
  5. Rogawski MA, Wenk GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003 Fall;9(3):275-308. [PubMed:14530799 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG: The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett. 2001 Jun 22;306(1-2):81-4. [PubMed:11403963 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Not Available
Specific Function:
Not Available
Gene Name:
CHRNA7
Uniprot ID:
Q693P7
Molecular Weight:
2987.635 Da
References
  1. Aracava Y, Pereira EF, Maelicke A, Albuquerque EX: Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther. 2005 Mar;312(3):1195-205. Epub 2004 Nov 2. [PubMed:15522999 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P, Caruso C, Lasaga M: Memantine agonist action at dopamine D2High receptors. Synapse. 2008 Feb;62(2):149-53. [PubMed:18000814 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (...
Gene Name:
GRIN1
Uniprot ID:
Q05586
Molecular Weight:
105371.945 Da
References
  1. Kotermanski SE, Wood JT, Johnson JW: Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J Physiol. 2009 Oct 1;587(Pt 19):4589-604. doi: 10.1113/jphysiol.2009.176297. Epub 2009 Aug 17. [PubMed:19687120 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C, Arndt P, Ulzheimer JC, Sonders MS, Baumann C, Waldegger S, Lang F, Koepsell H: Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52. [PubMed:9687576 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 06, 2016 03:56